Exagen (XGN) Revenue & Revenue Breakdown
Exagen Revenue Highlights
Latest Revenue (Y)
$66.58M
Latest Revenue (Q)
$17.24M
Main Segment (Y)
Reportable Segment
Exagen Revenue by Period
Exagen Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $66.58M | 19.65% |
| 2024-12-31 | $55.64M | 5.89% |
| 2023-12-31 | $52.55M | 15.33% |
| 2022-12-31 | $45.56M | -5.66% |
| 2021-12-31 | $48.30M | 15.07% |
| 2020-12-31 | $41.98M | 3.93% |
| 2019-12-31 | $40.39M | 24.50% |
| 2018-12-31 | $32.44M | 21.01% |
| 2017-12-31 | $26.81M | 49.38% |
| 2015-12-31 | $17.95M | 53.87% |
| 2014-12-31 | $11.66M | 281.77% |
| 2013-12-31 | $3.06M | 229.91% |
| 2012-12-31 | $926.00K | - |
Exagen generated $66.58M in revenue during NA 2025, up 19.65% compared to the previous quarter, and up 158.61% compared to the same period a year ago.
Exagen Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $17.24M | 0.24% |
| 2025-06-30 | $17.20M | 10.99% |
| 2025-03-31 | $15.50M | 13.50% |
| 2024-12-31 | $13.65M | 9.18% |
| 2024-09-30 | $12.51M | -16.97% |
| 2024-06-30 | $15.06M | 4.50% |
| 2024-03-31 | $14.41M | 4.72% |
| 2023-12-31 | $13.77M | 2.60% |
| 2023-09-30 | $13.42M | -5.10% |
| 2023-06-30 | $14.14M | 25.89% |
| 2023-03-31 | $11.23M | -12.52% |
| 2022-12-31 | $12.84M | -12.83% |
| 2022-09-30 | $14.73M | 64.32% |
| 2022-06-30 | $8.96M | -13.78% |
| 2022-03-31 | $10.39M | -18.09% |
| 2021-12-31 | $12.69M | 3.58% |
| 2021-09-30 | $12.25M | -4.08% |
| 2021-06-30 | $12.77M | 20.64% |
| 2021-03-31 | $10.59M | -16.43% |
| 2020-12-31 | $12.67M | 17.57% |
| 2020-09-30 | $10.78M | 20.42% |
| 2020-06-30 | $8.95M | -6.64% |
| 2020-03-31 | $9.58M | -6.17% |
| 2019-12-31 | $10.21M | -2.16% |
| 2019-09-30 | $10.44M | -0.33% |
| 2019-06-30 | $10.47M | 13.11% |
| 2019-03-31 | $9.26M | -3.95% |
| 2018-12-31 | $9.64M | 17.24% |
| 2018-09-30 | $8.22M | 5.68% |
| 2018-06-30 | $7.78M | 14.51% |
| 2018-03-31 | $6.79M | 52.73% |
| 2015-12-31 | $4.45M | -4.53% |
| 2015-09-30 | $4.66M | 4.27% |
| 2015-06-30 | $4.47M | 2.31% |
| 2015-03-31 | $4.37M | 3.07% |
| 2014-12-31 | $4.24M | 15.41% |
| 2014-09-30 | $3.67M | 55.79% |
| 2014-06-30 | $2.36M | 68.84% |
| 2014-03-31 | $1.40M | 27.72% |
| 2013-12-31 | $1.09M | 16.90% |
| 2013-09-30 | $935.00K | - |
Exagen generated $17.24M in revenue during Q3 2025, up 0.24% compared to the previous quarter, and up 114.47% compared to the same period a year ago.
Exagen Revenue Breakdown
Exagen Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Reportable Segment | $66.58M | - | - | - | - |
| Shipping and Handling | - | $3.10M | $2.50M | $2.70M | $2.10M |
Latest
Exagen's latest annual revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).
Quarterly Revenue by Product
| Product/Service | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $16.63M | $17.24M | $17.20M | $15.50M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shipping and Handling | - | - | - | - | $500.00K | $900.00K | $900.00K | $800.00K | $600.00K | $600.00K | $600.00K | $700.00K | $600.00K | $700.00K | $700.00K | $600.00K | $500.00K | $600.00K | $600.00K | $500.00K |
Latest
Exagen's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Reportable Segment (100.00%).
Exagen Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NEO | NeoGenomics | $727.33M | $187.80M |
| VNDA | Vanda Pharmaceuticals | $216.10M | $56.26M |
| LFCR | Lifecore Biomedical | $128.26M | $31.11M |
| SMTI | Sanara MedTech | $86.67M | $26.33M |
| SGHT | Sight Sciences | $77.36M | $19.91M |
| MDXH | MDxHealth | $70.19M | $19.83M |
| XGN | Exagen | $66.58M | $17.24M |
| TKNO | Alpha Teknova | $40.52M | $10.45M |
| ACRS | Aclaris Therapeutics | $7.83M | $3.30M |
| BIOA | BioAge Labs | - | $2.05M |